Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (648)	3/29/1999 6:30:00 AM
From: KAF	Read Replies (2) \| Respond to of 942

Agreed, there was alot of cautious selling involved with the FDA announcement (a potential bombshell which did not explode). The horizon looks clear for the coming Q.

To: Captain Jack who wrote (648)	3/29/1999 1:24:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

In addition to reply #656, Lehman also reiterated buy, target $95: Warner-Lambert Reiterated 'Buy' at Lehman Bloomberg News March 29, 1999, 7:56 a.m. ET Princeton, New Jersey, March 29 (Bloomberg Data) -- Warner-Lambert Co. (WLA US) was reiterated ''buy'' by analyst C. Anthony Butler at Lehman Brothers. The 12-month target price is $95.00 per share. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652